Company impresses with scientifically based ovulation tracker and underlying business model
ZURICH, 31-May-2018 — /EuropaWire/ — Credit Suisse subsidiary SVC Ltd. for Risk Capital for SMEs, founded in 2010, provides Swiss SMEs and start-up companies with a total of CHF 130 million in venture capital. With the investment in Ava, SVC AG is now making a further commitment in the field of medical technology (MedTech). In addition to the convincing product, business model and management, the promising growth potential of the company was also decisive for the investment decision.
As the leading bank for entrepreneurs, Credit Suisse is committed to strengthening and further promoting Switzerland as a business hub through various measures. This also includes the provision of venture capital to innovative SMEs with growth potential. SVC Ltd. for Risk Capital for SMEs, the investment vehicle created for this purpose eight years ago, has now made another MedTech investment as part of Ava’s current financing round. Together with robotics & automation and fintech, this area is one of SVC Ltd.’s three investment focuses.
Ava is a Swiss-based start-up based in Zurich and San Francisco. The company has developed a bracelet of the same name with a mobile app that provides women with information about their menstrual cycle by recording various physiological parameters. It also provides users with reliable data on their fertile phases, the course of their pregnancy and their general state of health.
For the independently acting Investment Committee of SVC Ltd., the sophisticated product, the management and the underlying business model were decisive for participating in the company’s “Series B” financing round, in which Ava was able to raise a total of 30 million US dollars. In addition, the Investment Committee considers MedTech to be one of the driving industries of the future, especially in Switzerland.
Didier Denat, Chairman of the Board of Directors of SVC Ltd. and Head of Corporate Banking & Investment Banking at Credit Suisse (Switzerland) Ltd., comments: “The commitment to Ava demonstrates the great potential that we believe the company has for further growth. With this product, Ava has succeeded in combining a fundamental topic for women with technological innovation, big data and machine learning. Ava’s success to date shows that MedTech is also becoming increasingly relevant for personal use and thus a consumer good. At the same time, Ava is an excellent example of the innovative power of the Swiss start-up and SME landscape.”
About “SVC Ltd. for Risk Capital for SMEs”
SVC Ltd. for Risk Capital for SMEs (SVC Ltd.) was founded in May 2010 in collaboration with the Swiss Venture Club as a wholly-owned subsidiary of Credit Suisse. Its stated aim is to create new jobs or secure existing ones and thus strengthen Switzerland’s position as a center for business and employment. SVC Ltd. provides small and medium-sized enterprises and young entrepreneurs with venture capital totaling around 130 million Swiss francs. To date, investments in 45 companies have been made. The beneficiaries are innovative companies in different stages of their life cycles from around the country. Helvetica Capital AG has been responsible for investment portfolio management on behalf of SVC AG since September 2015. The company is managed at strategic level by a broad-based Board of Directors with the support of an operations team.
Founded in Switzerland in 2014 by industry leaders in wearable technology, women’s health, and data science, Ava is a medical technology company dedicated to bringing innovation to women’s reproductive health. The Ava bracelet, which received The Bump “Best of Baby Tech CES 2017” award for fertility and pregnancy and the Women’s Health “Editors’ Choice” award, is the company’s first consumer-facing medical device. Ava uses sensor technology, clinical research, and data science to precisely monitor a woman’s menstrual cycle or pregnancy in real time. The company is also conducting clinical studies to adapt and expand its algorithms for use as a non-hormonal contraceptive device. Ava has operations in Zurich and San Francisco.
Credit Suisse AG is one of the world’s leading financial services providers and is part of the Credit Suisse group of companies (referred to here as ‘Credit Suisse’). Our strategy builds on Credit Suisse’s core strengths: its position as a leading wealth manager, its specialist investment banking capabilities and its strong presence in our home market of Switzerland. We seek to follow a balanced approach to wealth management, aiming to capitalize on both the large pool of wealth within mature markets as well as the significant growth in wealth in Asia Pacific and other emerging markets, while also serving key developed markets with an emphasis on Switzerland. Credit Suisse employs approximately 46‘370 people. The registered shares (CSGN) of Credit Suisse AG’s parent company, Credit Suisse Group AG, are listed in Switzerland and, in the form of American Depositary Shares (CS), in New York. Further information about Credit Suisse can be found at www.credit-suisse.com.
This document was produced by and the opinions expressed are those of Credit Suisse as of the date of writing and are subject to change. It has been prepared solely for information purposes and for the use of the recipient. It does not constitute an offer or an invitation by or on behalf of Credit Suisse to any person to buy or sell any security. Any reference to past performance is not necessarily a guide to the future. The information and analysis contained in this publication have been compiled or arrived at from sources believed to be reliable but Credit Suisse does not make any representation as to their accuracy or completeness and does not accept liability for any loss arising from the use hereof.
Copyright © 2018 Credit Suisse Group AG and/or its affiliates. All rights reserved.
Credit Suisse AG
tel. +41 844 33 88 44